Wedbush Reiterates Outperform on G1 Therapeutics, Maintains $5 Price Target

G1 Therapeutics, Inc. +3.60% Pre

G1 Therapeutics, Inc.

GTHX

2.30

2.30

+3.60%

0.00% Pre

Wedbush analyst David Nierengarten reiterates G1 Therapeutics (NASDAQ: GTHX) with a Outperform and maintains $5 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via